Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer
Feng Du, Wenmiao Wang, Yongsheng Wang, Ming Li, Anjie Zhu, Jiayu Wang, Ruigang Cai, Fei Ma, Ying Fan, Qing Li, Pin Zhang, Vladimir Todorović, Peng Yuan, Binghe Xu
Topics & Concepts
EpirubicinMedicineCarboplatinCyclophosphamideChemotherapyBreast cancerOncologyInternal medicineAdjuvantTriple-negative breast cancerCancerAdjuvant chemotherapyTriple negativeCisplatinBreast Cancer Treatment StudiesCancer Treatment and PharmacologyCancer Immunotherapy and Biomarkers